EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis

Günter Niegisch iD, Marc-Oliver Grimm iD, Fraence Hardtstock iD, Julia Krieger iD, Alexandra Starry iD, Ulrike Osowski, Silke Guenther, Barthold Deiters iD, Ulf Maywald, Thomas Wilke iD, Mairead Kearney

Future Oncology · 14.06.2024 · 20 (19) · 1351-1366

DOI: 10.2217/fon-2023-1065 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Future Oncology, online erschienen am 22.04.2024. Verfasst von Günter Niegisch und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University Hospital & Medical Faculty of the Heinrich-Heine-University, Düsseldorf, 40225, Germany. Hauptthemen laut MEDLINE: Carcinoma, Transitional Cell. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Merck (CrossRef Funder ID: 10.13039/100009945).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

This study assessed real-world treatment in patients with metastatic urothelial carcinoma (mUC) in Germany. Materials & methods: Patients diagnosed with mUC from 2015 to 2019 were identified in two claims databases: AOK PLUS and GWQ.

Results

3226 patients with mUC were analyzed; 1286 (39.9%) received systemic treatment within 12 months of diagnosis (platinum-based chemotherapy: 64.2%). Factors associated with receiving treatment were: younger age, male sex, less comorbidity and recent diagnosis. In AOK PLUS and GWQ populations, unadjusted median overall survival (interquartile range) from diagnosis in treated patients was 13.7 (6.8-32.9) and 13.8 (7.1-41.7) months, and in untreated patients was 3.0 (1.2-10.8) and 3.6 (1.2-18.8) months, respectively.

Conclusion

A significant proportion of patients with mUC in Germany receive no systemic treatment. What is this article about? This article reports the results from a study in Germany between 2015 and 2019 that investigated how advanced bladder cancer that has spread to other organs was treated and how long people lived after diagnosis. The study looked at systemic therapies, which means treatments that affect the entire body.What were the results? Only 40% of people diagnosed with advanced bladder cancer received systemic treatment within the first 12 months. Of those who did receive systemic treatment, the majority received combination therapy that included a chemotherapy drug containing platinum (64%). Systemic treatment was more likely to be given to people who were younger, less sick, male, or more recently diagnosed. After 12 months, 56% of treated people were still alive, compared with 26% of people without treatment. On average, people who received systemic treatment lived for about 14 months, while people without systemic treatment lived for only 3 to 4 months.What do the results of the study mean? Many people with advanced bladder cancer in Germany do not receive systemic treatment. People who receive treatment are likely to live longer than those who do not receive treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Transitional CellHumansMaleFemaleAgedRetrospective StudiesGermanyMiddle AgedTreatment OutcomeAged, 80 and overUrologic NeoplasmsUrinary Bladder NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Metastasis

Stichwörter der Autor:innen

first-line treatmentmetastatic urothelial carcinomaoverall survivalprogression-free survivalreal-world treatment patternsystemic treatmenttreatment discontinuation

Autor:innen und Institutionen

  • Department of Urology, University Hospital & Medical Faculty of the Heinrich-Heine-University, Düsseldorf, 40225, Germany.
  • Centre for Integrated Oncology (CIO) Düsseldorf, CIO Aachen Bonn Cologne Düsseldorf (ABCD), Düsseldorf, 40225, Germany.
  • Department of Urology, University Hospital Jena, Jena, 07747, Germany.
  • Cytel, Berlin, 10785, Germany.
  • Merck Healthcare Germany GmbH, Weiterstadt, 64331, Germany, an affiliate of Merck KGaA.
  • Merck Healthcare KGaA, Darmstadt, 64293, Germany.

ORCID-Profile: Günter Niegisch, Marc-Oliver Grimm, Fraence Hardtstock, Julia Krieger, Alexandra Starry, Barthold Deiters, Thomas Wilke

Förderung

  • Merck (CrossRef Funder ID: 10.13039/100009945)

Zitieren

APA

Niegisch, G., Grimm, M. O., Hardtstock, F., Krieger, J., Starry, A., Osowski, U., Guenther, S., Deiters, B., Maywald, U., Wilke, T., & Kearney, M. (2024). Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis. Future Oncology, 20(19), 1351-1366. https://doi.org/10.2217/fon-2023-1065

Vancouver

Niegisch G, Grimm MO, Hardtstock F, Krieger J, Starry A, Osowski U, et al. Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis. Future Oncology. 2024;20(19):1351-1366. doi:10.2217/fon-2023-1065

BibTeX
@article{Niegisch2024,
  author = {Niegisch, Günter and Grimm, Marc-Oliver and Hardtstock, Fraence and Krieger, Julia and Starry, Alexandra and Osowski, Ulrike and Guenther, Silke and Deiters, Barthold and Maywald, Ulf and Wilke, Thomas and Kearney, Mairead},
  title = {Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis},
  journal = {Future Oncology},
  year = {2024},
  volume = {20},
  number = {19},
  pages = {1351--1366},
  doi = {10.2217/fon-2023-1065}
}
Kostenlos starten →